Prithwish Banerji has taken on the role of Commercial Director at Abbott India Ltd., overseeing the Women’s Health, Metabolics, and International Business divisions. With over two decades of experience blending sales and marketing expertise, he brings a wealth of leadership experience to this new position. Prithwish’s career trajectory is marked by his work in strategic business planning and execution, having held senior roles at leading multinational companies. His expertise spans industries including pharmaceuticals, OTC, FMCG, and more, making him a key figure in business transformation and growth strategies.
Before joining Abbott, Prithwish served as Vice President at Cipla, where he led various business units, driving growth and efficiency. His tenure at Cipla included roles as Senior Director & Group Business Head, as well as leadership in cost-saving initiatives and new market entries. Prithwish’s deep understanding of the Indian pharmaceutical market, particularly in launching patented products and transforming GTM models, has been instrumental in his success across companies like Pfizer, Boehringer Ingelheim, GSK Consumer Healthcare, and Unilever.
In his new role at Abbott India, Prithwish will continue to leverage his extensive experience in steering high-impact projects, especially in market expansion and product launches. His leadership will likely contribute significantly to Abbott’s ongoing success in India’s competitive healthcare sector, focusing on building sustainable businesses and enhancing consumer engagement. With his proven track record in establishing new businesses and transforming operations, Abbott India’s growth under his direction is expected to accelerate.
Prithwish Banerji’s transition to Abbott marks an exciting chapter in his career, one that promises to bring innovative solutions and deeper market penetration in the healthcare industry. His leadership style, honed over years of managing top-tier companies, is set to play a pivotal role in Abbott’s future endeavors in India and beyond.